AAAna Carolina Peçanha Antonio

Ana Carolina Peçanha Antonio

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Ana Carolina Peçanha Antonio has a total of 119 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Seven versus 14 days of antimicrobial therapy for severe multidrug-resistant Gram-negative bacterial infections in intensive care unit patients (OPTIMISE): a randomised, open-label, non-inferiority clinical trial

    by Beatriz Arns, Andre C. Kalil, Guilherme G. L. Sorio, Emerson Boschi, Ana Carolina Peçanha Antonio, Juliana Peçanha Antonio, Daniella Cunha Birriel, Daniel Haase Lanziotti, Frederico da Cunha Abbott, Glecia Carla Rocha, et al.

    Shorter courses of antimicrobial therapy have been shown to be non-inferior to longer durations for the management of several infections. However, data on critically ill patients with severe infections by multidrug-resistant Gram-negative bacteria (MDR-GNB) are scarce. In the duratiOn of theraPy in severe infecTIons by MultIdrug-reSistant gram-nEgative bacteria (OPTIMISE) trial, we assessed the non-inferiority of 7-day versus 14-day antimicrobial therapy for patients with intensive care unit (ICU)-acquired severe infections by MDR-GNB. This was a randomised multicenter, open-label, parallel controlled, non-inferiority trial. Adult patients with severe infections by MDR-GNB initiated ≥ 48 h of ICU admission were eligible if they were hemodynamically stable and without fever > 48 h on the 7th day of appropriate antimicrobial therapy. Patients were 1:1 randomised to discontinue antimicrobial therapy on the 7th (± 1) day or to continue for a total of 14 (± 1) days. The primary outcome was clinical failure, defined as death or relapse of infection within 28 days of randomisation. An upper edge of the two-tailed 95% confidence interval (CI) of the delta between the clinical failure rate in the 7- and the 14-day lower than 10% in both intention-to-treat (ITT) and per protocol (PP) analyses was set as the non-inferiority criteria. A total of 106 patients composed the ITT population: 59 and 47 allocated to 7- and 14-day groups, respectively. The PP population included 75 patients: 47 and 28 in the 7- and 14-day groups, respectively. Clinical failure occurred in 42.4% and 44.7% of the ITT population in 7- and 14-day groups, respectively, (risk difference (RD) − 2.3, 95%CI − 21.3 to 16.7), and in 46.8% and 50.0% of the PP population in 7- and 14-day groups, respectively (RD − 3.2, 95%CI − 26.6 to 20.2). Most infections were of the respiratory tract (73/68.9%) and caused by carbapenem-resistant Enterobacterales (42/39.6%). The study was interrupted before reaching planned sample size due to low recruitment rate. The OPTIMISE trial could not determine the non-inferiority of 7-day compared to 14-day therapy for severe infections caused by MDR-GNB due to early termination related to the low recruitment rate. Trial registration: NCT05210387 on January 13, 2022.


  • Composite endpoints in COVID-19 randomized controlled trials: a systematic review

    by Pedro Nascimento Martins, Mateus Henrique Toledo Lourenço, Gabriel Paz Souza Mota, Alexandre Biasi Cavalcanti, Ana Carolina Peçanha Antonio, Fredi Alexander Diaz-Quijano

    Background/Aims: This study aimed to determine the prevalence of ordinal, binary, and numerical composite endpoints among coronavirus disease 2019 trials and the potential bias attributable to their use. Methods: We systematically reviewed the Cochrane COVID-19 Study Register to assess the prevalence, characteristics, and bias associated with using composite endpoints in coronavirus disease 2019 randomized clinical trials. We compared the effect measure (relative risk) of composite outcomes and that of its most critical component (i.e. death) by estimating the Bias Attributable to Composite Outcomes index [ln(relative risk for the composite outcome)/ln(relative risk for death)]. Results: Composite endpoints accounted for 152 out of 417 primary endpoints in coronavirus disease 2019 randomized trials, being more frequent among studies published in high-impact journals. Ordinal endpoints were the most common (54% of all composites), followed by binary or time-to-event (34%), numerical (11%), and hierarchical (1%). Composites predominated among trials enrolling patients with severe disease when compared to trials with a mild or moderate case mix (odds ratio = 1.72). Adaptations of the seven-point World Health Organization scale occurred in 40% of the ordinal primary endpoints, which frequently underwent dichotomization for the statistical analyses. Mortality accounted for a median of 24% (interquartile range: 6%–48%) of all events when included in the composite. The median point estimate of the Bias Attributable to Composite Outcomes index was 0.3 (interquartile range: −0.1 to 0.7), being significantly lower than 1 in 5 of 24 comparisons. Discussion: Composite endpoints were used in a significant proportion of coronavirus disease 2019 trials, especially those involving severely ill patients. This is likely due to the higher anticipated rates of competing events, such as death, in such studies. Ordinal composites were common but often not fully appreciated, reducing the potential gains in information and statistical efficiency. For studies with binary composites, death was the most frequent component, and, unexpectedly, composite outcome estimates were often closer to the null when compared to those for mortality death. Numerical composites were less common, and only two trials used hierarchical endpoints. These newer approaches may offer advantages over traditional binary and ordinal composites; however, their potential benefits warrant further scrutiny. Conclusion: Composite endpoints accounted for more than a third of coronavirus disease 2019 trials’ primary endpoints; their use was more common among studies that included patients with severe disease and their point effect estimates tended to underestimate those for mortality.


  • Open Access

    Impacto nas funções pulmonar, cardíaca e renal e na qualidade de vida a longo prazo após internação por síndrome do desconforto respiratório agudo por COVID-19: protocolo do Estudo 3 Pós-COVID Brasil

    by Fernando Luís Scolari, Marciane Maria Rover, Geraldine Trott, Mariana Motta Dias da Silva, Denise de Souza, Raine Fogliati de Carli Schardosim, Rosa da Rosa Minho dos Santos, Emelyn de Souza Roldão, Duane Mocellin, Jennifer Menna Barreto de Souza, et al.

    RESUMO Fundamento: As evidências acerca das sequelas a longo prazo após internação por síndrome do desconforto respiratório agudo por COVID-19 ainda são escassas. Objetivo: Avaliar alterações nas funções pulmonar, cardíaca e renal e na qualidade de vida após internação por síndrome do desconforto respiratório agudo secundária à COVID-19. Métodos: Trata-se de estudo multicêntrico, caso-controle, incluindo 220 participantes. Os casos serão definidos como pacientes hospitalizados por síndrome do desconforto respiratório agudo devido à COVID-19. No Grupo Controle, serão selecionados indivíduos sem histórico de hospitalização nos últimos 12 meses ou sintomas a longo prazo de COVID-19. Todos os indivíduos serão submetidos à espirometria pulmonar com teste de difusão pelo monóxido de carbono, tomografia de tórax, ressonância magnética cardíaca e renal com gadolínio, ergoespirometria, creatinina sérica e urinária, proteínas totais e microalbuminúria urinária, além de questionários de qualidade de vida. Os casos serão avaliados 12 meses após a alta hospitalar e os controles, 90 dias após a inclusão no estudo. Para todas as análises estatísticas, será assumido como significativo o valor p < 0,05. Resultados: O desfecho primário do estudo foi definido com a capacidade de difusão pulmonar aferida para o monóxido de carbono a partir de 12 meses. Os demais parâmetros das funções pulmonar, cardíacas e renal e da qualidade de vida foram definidos como desfechos secundários. Conclusão: Este estudo visa determinar as sequelas a longo prazo nas funções pulmonar, cardíaca e renal e na qualidade de vida de pacientes internados por síndrome do desconforto respiratório agudo devido à COVID-19 na população brasileira.

  • Open Access

    Impact on pulmonary, cardiac, and renal function and long-term quality of life after hospitalization for acute respiratory distress syndrome due to COVID-19: Protocol of the Post-COVID Brazil 3 study

    by Fernando Luís Scolari, Marciane Maria Rover, Geraldine Trott, Mariana Motta Dias da Silva, Denise de Souza, Raine Fogliati de Carli Schardosim, Rosa da Rosa Minho dos Santos, Emelyn de Souza Roldão, Duane Mocellin, Jennifer Menna Barreto de Souza, et al.

    Rationale: Evidence about long-term sequelae after hospitalization for acute respiratory distress syndrome due to COVID-19 is still scarce. Purpose: To evaluate changes in pulmonary, cardiac, and renal function and in quality of life after hospitalization for acute respiratory distress syndrome secondary to COVID-19. Methods: This will be a multicenter case–control study of 220 participants. Eligible are patients who are hospitalized for acute respiratory distress syndrome due to COVID-19. In the control group, individuals with no history of hospitalization in the last 12 months or long-term symptoms of COVID-19 will be selected. All individuals will be subjected to pulmonary spirometry with a carbon monoxide diffusion test, chest tomography, cardiac and renal magnetic resonance imaging with gadolinium, ergospirometry, serum and urinary creatinine, total protein, and urinary microalbuminuria, in addition to quality-of-life questionnaires. Patients will be evaluated 12 months after hospital discharge, and controls will be evaluated within 90 days of inclusion in the study. For all the statistical analyses, p < 0.05 is the threshold for significance. Results: The primary outcome of the study will be the pulmonary diffusing capacity for carbon monoxide measured after 12 months. The other parameters of pulmonary, cardiac, and renal function and quality of life are secondary outcomes. Conclusion: This study aims to determine the long-term sequelae of pulmonary, cardiac, and renal function and the quality of life of patients hospitalized for acute respiratory distress syndrome due to COVID-19 in the Brazilian population.


  • Open Access

    Published benefits of ivermectin use in Itajaí, Brazil for COVID-19 infection, hospitalisation, and mortality are entirely explained by statistical artefacts

    by Robin Mills, Ana Carolina Peçanha Antonio, Greg Tucker-Kellogg

    Background Two recent publications by Kerr et al. (Cureus 14(1):e21272; Cureus 14(8): e28624) reported dramatic effects of prophylactic ivermectin use for both prevention of COVID-19 and reduction of COVID-19-related hospitalisation and mortality, including a dose-dependent effect of ivermectin prophylaxis. These papers have gained an unusually large public influence: they were incorporated into debates around COVID-19 policies and may have contributed to decreased trust in vaccine efficacy and public health authorities more broadly. Both studies were based on retrospective observational analysis of city-wide registry data from the city of Itajaí, Brazil from July-December 2020. Methods Starting with initially identified sources of error, we conducted a revised statistical analysis of available data, including data made available with the original papers and public data from the Brazil Ministry of Health. We identified additional uncorrected sources of bias and errors from the original analysis, including incorrect subject exclusion and missing subjects, an enrolment time bias, and multiple sources of immortal time bias. In models assuming no actual effect from ivermectin use, we conducted Monte Carlo simulations to estimate the contribution of these biases to any observed effect. Results Untreated statistical artefacts and methodological errors alone lead to dramatic apparent risk reduction associated with ivermectin use in both studies. The magnitude of apparent risk reduction from these artefacts is comparable to the results reported by the studies themselves, including apparent protection from infection, hospitalisation, and death, and including the reported apparent dose-response relationship. Conclusions The inference of ivermectin efficacy reported in both papers is unsupported, as the observed effects are entirely explained by untreated statistical artefacts and methodological errors. Our re-analysis calls for caution in interpreting highly publicised observational studies and highlights the importance of common sources of bias in clinical research.

  • Open Access

    Palliative extubation experience in a community hospital in southern Brazil

    by Ana Carolina Peçanha Antonio, Juliana Peçanha Antonio

    Sustaining invasive mechanical ventilation may inappropriately prolong the dying process and perpetuate states worse than death in end-of-life care. Even though withdrawing the ventilator in this circumstance is a well-established practice worldwide1 1 Efstathiou N, Vanderspank-Wright B, Vandyk A, Al-Janabi M, Daham Z, Sarti A, et al. Terminal withdrawal of mechanical ventilation in adult intensive care units: a systematic review and narrative synthesis of perceptions, experiences and practices. Palliat Med. 2020;34(9):1140-64. https://doi.org/10.1177/0269216320935002 https://doi.org/10.1177/0269216320935002... , Brazilian physicians are far more likely to withhold than withdraw life-sustaining treatments2 2 Yaguchi A, Truog RD, Curtis JR, Luce JM, Levy MM, Mélot C, et al. International differences in end-of-life attitudes in the intensive care unit: results of a survey. Arch Intern Med. 2005;165(17):1970-5. https://doi.org/10.1001/archinte.165.17.1970 https://doi.org/10.1001/archinte.165.17.... –5 5 Furtado RA, Tonial CT, Costa CAD, Andrades GRH, Crestani F, Bruno F, et al. End-of-life practices in patients admitted to pediatric intensive care units in Brazil: a retrospective study. J Pediatr (Rio J). 2021;97(5):525-30. https://doi.org/10.1016/j.jped.2020.10.017 https://doi.org/10.1016/j.jped.2020.10.0... .


  • Open Access

    The challenges of low and middle-income countries in healthcare management after COVID-19

    by Ana Carolina Peçanha Antonio, Seleno Glauber de Jesus-Silva

    More than two years after WHO declared the novel coronavirus (COVID-19) outbreak a pandemic, a year after deploying the first COVID vaccine, and as we approach nearly 6.5 million infection-related deaths1, we wonder, as Brazilian front-line physicians, what are the lessons we should have learned. Accordingly, healthcare was the first of all systems affected by COVID-19, particularly in developing nations. Despite the additional costs of unemployment, supply chain disturbances, finance expenses to support businesses, and millions of children deprived of education, we still witness the abundance of daily clinical practices of low-value care, failed public health policies, and scientific researches of controversial relevance and not centered in the patient.

  • Top Cited Papers
    Open Access

    Assessing the burden of COVID-19 in developing countries: systematic review, meta-analysis and public policy implications

    by Andrew T Levin, Nana Owusu-Boaitey, Sierra Pugh, Bailey K Fosdick, Anthony B Zwi, Anup Malani, Satej Soman, Lonni Besançon, Ilya Kashnitsky, Sachin Ganesh, et al.

    Introduction The infection fatality rate (IFR) of COVID-19 has been carefully measured and analysed in high-income countries, whereas there has been no systematic analysis of age-specific seroprevalence or IFR for developing countries. Methods We systematically reviewed the literature to identify all COVID-19 serology studies in developing countries that were conducted using representative samples collected by February 2021. For each of the antibody assays used in these serology studies, we identified data on assay characteristics, including the extent of seroreversion over time. We analysed the serology data using a Bayesian model that incorporates conventional sampling uncertainty as well as uncertainties about assay sensitivity and specificity. We then calculated IFRs using individual case reports or aggregated public health updates, including age-specific estimates whenever feasible. Results In most locations in developing countries, seroprevalence among older adults was similar to that of younger age cohorts, underscoring the limited capacity that these nations have to protect older age groups. Age-specific IFRs were roughly 2 times higher than in high-income countries. The median value of the population IFR was about 0.5%, similar to that of high-income countries, because disparities in healthcare access were roughly offset by differences in population age structure. Conclusion The burden of COVID-19 is far higher in developing countries than in high-income countries, reflecting a combination of elevated transmission to middle-aged and older adults as well as limited access to adequate healthcare. These results underscore the critical need to ensure medical equity to populations in developing countries through provision of vaccine doses and effective medications.


  • Open Access

    Research integrity in times of pandemic

    by Seleno Glauber de Jesus-Silva, Ana Carolina Peçanha Antonio

    In 1994, Douglas Graham Altman, one of the greatest statisticians of all time, wrote "We need less research, better research, and research done for good reasons". Twenty-seven years ago, Altman pointed out that the system favored unscientific behavior and that "bad science" was easy to publish, highlighting the financial implications of this amount of poorly designed research, with erroneous statistical methods, unrepresentative samples, or fraud. The covid-19 pandemic has once again put clinical research in check. The pressure for urgent responses was unprecedented. Knowledge of the origin of the virus, the transmission dynamics, the pathophysiology of the disease, efficient pharmacological and non-pharmacological measures would be counted in lives - and economies, and in governments.


  • Open Access

    The Correspondence between Fluid Balance and Body Weight Change Measurements in Critically Ill Adult Patients

    by Ana Carolina Peçanha Antonio, Vivian Rodrigues Fernandes, Karina de Oliveira Azzolin

    Introduction: Positive fluid status has been associated with a worse prognosis in intensive care unit (ICU) patients. Given the potential for errors in the calculation of fluid balance totals and the problem of accounting for indiscernible fluid losses, measurement of body weight change is an alternative non-invasive method commonly used for estimating body fluid status. The objective of the study is to compare the measurements of fluid balance and body weight changes over time and to assess their association with ICU mortality. Methods: This prospective observational study was conducted in the 34-bed multidisciplinary ICU of a tertiary teaching hospital in southern Brazil. Adult patients were eligible if their expected length of stay was more than 48 hours, and if they were not receiving an oral diet. Clinical demographic data, daily and cumulative fluid balance with and without indiscernible water loss, and daily and total body weight changes were recorded. Agreement between daily fluid balance and body weight change, and between cumulative fluid balance and total body weight change were calculated. Results: Cumulative fluid balance and total body weight change differed significantly among survivors and non survivors respectively, +2.53L versus +5.6L (p= 0.012) and -3.05kg vs -1.1kg (p= 0.008). The average daily difference between measured fluid balance and body weight was +0.864 L/kg with a wide interval: -3.156 to +4.885 L/kg, which remained so even after adjustment for indiscernible losses (mean bias: +0.288; limits of agreement between -3.876 and +4.452 L/kg). Areas under ROC curve for cumulative fluid balance, cumulative fluid balance with indiscernible losses and total body weight change were, respectively, 0.65, 0.56 and 0.65 (p= 0.14). Conclusion: The results indicated the absence of correspondence between fluid balance and body weight change, with a more significant discrepancy between cumulative fluid balance and total body weight change. Both fluid balance and body weight changes were significantly different among survivors and non-survivors, but neither measurement discriminated ICU mortality.